CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $147,840.00 in Stock

March 13, 2026 by InsiderTrades.com

Key Points

CEO Samarth Kulkarni sold 9,798 shares on March 11 at an average price of $52.80 for $517,334, cutting his position ~3.99% to 235,558 shares; he also completed several larger insider sales earlier this year (30,000 and 60,000 shares).
Weak quarterly results: CRISPR reported EPS of ($1.37) vs. ($1.15) expected and revenue of $0.86M (vs. $4.72M est.), a 97.8% year‑over‑year revenue decline, contributing to recent share weakness.
Financing and sentiment pressure: The company priced an upsized $550M convertible senior note offering (due 2031), which coincided with sharp intraday declines, and Wall Street views remain mixed with a consensus rating of "Hold" and a $64.24 target.

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James Kasinger sold 2,800 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $147,840.00. Following the completion of the sale, the general counsel owned 87,815 shares in the company, valued at $4,636,632. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CRISPR Therapeutics Stock Down 1.2%

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

NASDAQ CRSP traded down $0.59 during trading on Friday, reaching $48.28. 1,272,153 shares of the stock traded hands, compared to its average volume of 1,980,759. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm has a market cap of $4.63 billion, a price-to-earnings ratio of -7.38 and a beta of 1.72. The stock's 50-day moving average price is $54.20 and its 200 day moving average price is $57.28.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The firm had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same quarter last year, the business posted ($1.01) earnings per share. The company's revenue for the quarter was down 97.8% on a year-over-year basis. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

A number of hedge funds have recently modified their holdings of CRSP. Royal Bank of Canada lifted its stake in CRISPR Therapeutics by 28.2% in the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company's stock valued at $4,856,000 after acquiring an additional 31,392 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth approximately $861,000. Woodline Partners LP grew its stake in shares of CRISPR Therapeutics by 34.3% during the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company's stock worth $4,645,000 after acquiring an additional 34,883 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of CRISPR Therapeutics by 288.6% in the second quarter. Bank of New York Mellon Corp now owns 301,959 shares of the company's stock valued at $14,687,000 after purchasing an additional 224,257 shares during the last quarter. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of CRISPR Therapeutics in the second quarter worth $33,000. 69.20% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Citigroup restated a "buy" rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Morgan Stanley reiterated an "underweight" rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. TD Cowen increased their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a "hold" rating in a research note on Friday, February 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a research note on Wednesday, January 21st. Finally, Bank of America reduced their price target on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a "buy" rating for the company in a report on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and a consensus target price of $64.24.

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

Get Our Latest Report on CRSP

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

Positive Sentiment: FY‑2025 commercial progress: CRSP reported $116M in FY‑25 revenue driven by CASGEVY, with $54M in Q4, supporting longer‑term revenue potential. CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth
Positive Sentiment: Institutional buying noted: Coverage flagged that ARK Invest bought CRSP shares, signaling institutional interest that can provide buying support despite volatility. CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares
Positive Sentiment: Analyst tweaks modestly constructive: Brookline Capital’s updates include small upward revisions to near‑term FY2026/FY2027 EPS (less negative), which slightly improves the near‑term earnings outlook (changes are minor).
Neutral Sentiment: Retail/investor attention rose: Zacks/Yahoo flagged CRSP among most‑searched stocks, indicating higher retail interest that can amplify moves but is not a directional signal by itself. Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Neutral Sentiment: Short‑interest reporting appears noisy: recent short‑interest entries in feeds show inconsistent/zero values (likely data artifacts) — not a clear signal on positioning.
Negative Sentiment: Convertible note offering: CRISPR priced an upsized $550M convertible senior notes offering due 2031. Markets often react negatively to large convertible financings because of potential dilution and share supply; that offering coincided with sharp intraday weakness. CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales of shares (~9,798 and 2,800 shares, respectively), which can be perceived as a near‑term negative signal for sentiment. Insider Sales by CEO Samarth Kulkarni
Negative Sentiment: Recent sharp intraday declines: media coverage noted multi‑percent drops in recent sessions after the financing news, amplifying volatility and likely contributing to continued selling pressure. CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.